Morphic Holding Inc MORF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MORF is a good fit for your portfolio.
News
-
Shareholder Alert: Ademi LLP investigates whether Morphic Holding, Inc. has obtained a Fair Price for its Public Shareholders
-
Morphic Holding Shares Take Flight on Acquisition by Eli Lilly
-
Eli Lilly to pay $3.2 billion in cash to buy this biotech with an IBD treatment
-
MORF Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Morphic Holding, Inc. Is Fair to Shareholders
-
Eli Lilly to Buy Morphic Holding for $3.2 Billion — Update
-
Eli Lilly to Buy Morphic Holding for $3.2 Billion
-
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
Trading Information
- Previous Close Price
- $31.84
- Day Range
- $55.60–55.99
- 52-Week Range
- $19.35–62.08
- Bid/Ask
- $55.77 / $56.30
- Market Cap
- $2.79 Bil
- Volume/Avg
- 282 / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 121
- Website
- https://www.morphictx.com
Comparables
Valuation
|
Metric
|
MORF
|
EWTX
|
NGM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.21 | 3.65 | 0.86 |
Price/Sales | — | — | 28.76 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MORF
|
EWTX
|
NGM
|
|---|---|---|---|
Quick Ratio | 37.20 | 36.49 | 7.18 |
Current Ratio | 38.17 | 37.08 | 7.79 |
Interest Coverage | — | — | — |
Quick Ratio
No chart available
Profitability
|
Metric
|
MORF
|
EWTX
|
NGM
|
|---|---|---|---|
Return on Assets (Normalized) | −18.85% | −23.18% | −49.51% |
Return on Equity (Normalized) | −19.43% | −24.45% | −57.34% |
Return on Invested Capital (Normalized) | −23.26% | −28.92% | −61.20% |
Return on Assets
No chart available
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Dtlhjkpghj | Fhtt | $636.3 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Mgrpkln | Mbvfzql | $124.4 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Wdtpddpq | Syvfftp | $115.9 Bil | |||
| Moderna Inc
MRNA
| Pvbylws | Dblyg | $44.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xxxvchzs | Bsrrkj | $32.3 Bil | |||
| argenx SE ADR
ARGX
| Glxsqzccm | Wwws | $25.8 Bil | |||
| BioNTech SE ADR
BNTX
| Dxxbpjh | Qyr | $19.4 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Kbcfpvkzl | Dgwwtt | $15.7 Bil | |||
| United Therapeutics Corp
UTHR
| Hlyndvc | Rfqh | $14.1 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Vkkkmzrbl | Hctpb | $11.6 Bil |